Summit Therapeutics PLC (SMMT) - Total Liabilities
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has total liabilities worth $122.20 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Summit Therapeutics PLC's assets to evaluate the company's liquid asset resilience ratio.
Summit Therapeutics PLC - Total Liabilities Trend (2003–2025)
This chart illustrates how Summit Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Summit Therapeutics PLC's balance sheet.
Summit Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Summit Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Harmony Gold Mining Company Ltd
BA:HMY
|
Argentina | AR$22.85 Billion |
|
Pershing Square Inc.
NYSE:PS
|
USA | $106.00 Million |
|
KUAISHOU TECHNOLOGY CL.B
F:5Y0
|
Germany | €84.82 Billion |
|
Euronext N.V.
PA:ENX
|
France | €322.90 Billion |
|
REA Group Limited
F:R9C
|
Germany | €881.30 Million |
|
Coca-Cola Consolidated Inc.
NASDAQ:COKE
|
USA | $5.36 Billion |
|
Fox Corp Class A
NASDAQ:FOXA
|
USA | $10.37 Billion |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
China | CN¥11.08 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Summit Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Summit Therapeutics PLC to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Summit Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Summit Therapeutics PLC (2003–2025)
The table below shows the annual total liabilities of Summit Therapeutics PLC from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $68.52 Million | +83.17% |
| 2024-12-31 | $37.41 Million | -62.26% |
| 2023-12-31 | $99.12 Million | -77.38% |
| 2022-12-31 | $438.18 Million | +1864.49% |
| 2021-12-31 | $22.30 Million | +31.77% |
| 2020-12-31 | $16.93 Million | +18.03% |
| 2019-12-31 | $14.34 Million | -39.58% |
| 2018-12-31 | $23.74 Million | -61.96% |
| 2017-12-31 | $62.40 Million | +21.53% |
| 2016-12-31 | $51.35 Million | +814.38% |
| 2015-12-31 | $5.62 Million | -42.07% |
| 2014-12-31 | $9.69 Million | +132.02% |
| 2013-12-31 | $4.18 Million | +73.35% |
| 2012-12-31 | $2.41 Million | +3.02% |
| 2011-12-31 | $2.34 Million | +4.64% |
| 2010-12-31 | $2.24 Million | -56.61% |
| 2009-12-31 | $5.15 Million | -33.65% |
| 2008-12-31 | $7.77 Million | -49.24% |
| 2007-12-31 | $15.30 Million | +141.81% |
| 2006-12-31 | $6.33 Million | +153.93% |
| 2005-12-31 | $2.49 Million | +611.58% |
| 2004-12-31 | $350.21K | +9500.03% |
| 2003-12-31 | $3.65K | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more